Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Ussher, D. Drucker (2014)
Cardiovascular actions of incretin-based therapies.Circulation research, 114 11
I. Anand, L. Fisher, Y. Chiang, R. Latini, S. Masson, A. Maggioni, R. Glazer, G. Tognoni, J. Cohn (2003)
Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)Circulation: Journal of the American Heart Association, 107
J. Swan, S. Anker, C. Walton, I. Godsland, A. Clark, F. Leyva, J. Stevenson, A. Coats (1997)
Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.Journal of the American College of Cardiology, 30 2
M. Pfeffer, B. Claggett, R. Diaz, K. Dickstein, H. Gerstein, L. Køber, Francesca Lawson, Lin Ping, Xiaodan Wei, E. Lewis, A. Maggioni, J. McMurray, J. Probstfield, M. Riddle, S. Solomon, J. Tardif (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.The New England journal of medicine, 373 23
E. Abel (2005)
Myocardial insulin resistance and cardiac complications of diabetes.Current drug targets. Immune, endocrine and metabolic disorders, 5 2
F. Zannad, C. Cannon, W. Cushman, G. Bakris, V. Menon, Alfonso Perez, P. Fleck, C. Mehta, S. Kupfer, Craig Wilson, H. Lam, W. White (2015)
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trialThe Lancet, 385
S. Blecker, Margaret Paul, Glen Taksler, G. Ogedegbe, S. Katz (2013)
Heart failure–associated hospitalizations in the United States.Journal of the American College of Cardiology, 61 12
G. Sokos, L. Nikolaidis, S. Mankad, D. Elahi, R. Shannon (2006)
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.Journal of cardiac failure, 12 9
M. Davies, S. Bain, S. Atkin, P. Rossing, D. Scott, M. Shamkhalova, H. Bosch‐Traberg, A. Syrén, G. Umpierrez (2015)
Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical TrialDiabetes Care, 39
Sophie Clarke, L. McCormick, D. Dutka (2014)
Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1Cardiovascular Diabetology, 13
M. Packer, A. Coats, M. Fowler, H. Katus, H. Krum, P. Mohacsi, J. Rouleau, M. Tendera, A. Castaigne, E. Roecker, M. Schultz, D. DeMets (2001)
Effect of carvedilol on survival in severe chronic heart failure.The New England journal of medicine, 344 22
P. Grigoropoulou, I. Eleftheriadou, C. Zoupas, E. Diamanti-Kandarakis, N. Tentolouris (2013)
Incretin-based therapies for type 2 diabetes mellitus: effects on insulin resistance.Current diabetes reviews, 9 5
Jennifer Green, M. Bethel, P. Armstrong, J. Buse, S. Engel, Jyotsna Garg, R. Josse, K. Kaufman, J. Koglin, S. Korn, J. Lachin, Darren Mcguire, M. Pencina, E. Standl, P. Stein, S. Suryawanshi, F. Werf, E. Peterson, R. Holman (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.The New England journal of medicine, 373 3
B. Scirica, E. Braunwald, I. Raz, M. Cavender, D. Morrow, P. Jarolím, J. Udell, Ofri Mosenzon, K. Im, A. Umez-Eronini, P. Pollack, B. Hirshberg, R. Frederich, B. Lewis, Darren Mcguire, J. Davidson, P. Steg, Deepak Bhatt (2015)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.Circulation
L. Nikolaidis, Anthony Sturzu, C. Stolarski, D. Elahi, You-tang Shen, R. Shannon (2004)
The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy.Cardiovascular research, 61 2
B. Zinman, C. Wanner, J. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O. Johansen, H. Woerle, U. Broedl, S. Inzucchi (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.The New England journal of medicine, 373 22
M. Velez, Edward Peterson, K. Wells, T. Swadia, Hani, N. Sabbah, L. Williams, D. Lanfear (2015)
Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes.Journal of cardiac failure, 21 1
Shiying Wu, I. Hopper, M. Skiba, H. Krum (2014)
Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants.Cardiovascular therapeutics, 32 4
S. Marso, N. Poulter, S. Nissen, M. Nauck, B. Zinman, G. Daniels, S. Pocock, W. Steinberg, R. Bergenstal, J. Mann, L. Ravn, K. Frandsen, A. Moses, J. Buse (2013)
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.American heart journal, 166 5
K. Margulies, K. Anstrom, Adrian Hernandez, M. Redfield, M. Shah, E. Braunwald, T. Cappola (2014)
GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction: Design and Rationale for the Functional Impact of GLP-1 for Heart Failure Treatment StudyCirculation: Heart Failure, 7
J. Lachin (1999)
Worst-rank score analysis with informatively missing observations in clinical trials.Controlled clinical trials, 20 5
BM Scirica, E Braunwald, I Raz (2014)
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial [published correction appears in Circulation. 2015;132(15):e198], 130
Key PointsQuestionDoes therapy with the glucagon-like peptide 1 agonist liraglutide improve clinical stability in patients with advanced heart failure? FindingsIn this randomized clinical trial of 300 adults with advanced heart failure, liraglutide had no significant effect on posthospitalization clinical stability based on a global rank score of time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level. There was no benefit observed among the 178 patients with type 2 diabetes. MeaningThese findings do not support the use of liraglutide for improving clinical stability in patients with advanced heart failure and reduced left ventricular ejection fraction.
JAMA – American Medical Association
Published: Aug 2, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.